Veterinary enrofloxacin solid lipid nanosuspension and preparation method thereof

Abstract

The invention belongs to the technical field of preparation of veterinary drugs and particularly relates to a veterinary enrofloxacin solid lipid nanosuspension and a preparation method thereof. The technological production of a preparation is implemented with a high-pressure homogenization technique. In terms of W / V, a suspension injection is prepared from 12%-35% of a solid lipid substrate, 2%-6% of crude enrofloxacin, 0.2%-4% of an active agent, 0.2%-1% of an antioxidant and the balance of sterile water. The solid lipid substrate is good in physiological compatibility and biodegradable, theencapsulation efficiency and drug loading capacity of nanoparticles are high, the preparation method is simple, the production cost is low, and large-scale industrial production is easy. The solid lipid nanosuspension has an obvious slow-release effect, in-vivo absorption and in-cell intake of active molecules can be increased, clinical administration times can be reduced, and the nanosuspensionis non-irritant to target animals and can be used for preventing and treating bacterial digestive tract and respiratory diseases of pigs and chicken.

Description

Technical field [0001] The invention belongs to the field of preparation of veterinary drug preparations, and specifically relates to an enrofloxacin solid lipid nano suspension for veterinary use and a preparation method thereof. Background technique [0002] Enrofloxacin is a synthetic animal-specific fluoroquinolone antibacterial drug, which can achieve antibacterial effect by inhibiting bacterial DNA helicase. It has a broad antibacterial spectrum, strong bactericidal activity, wide distribution in the body, small toxic and side effects, and other antibacterial The drug has no cross-resistance and other characteristics, and is mainly used to treat animal bacterial infectious diseases. Although enrofloxacin has strong antibacterial activity, its weak ability to accumulate in cells results in limited clinical treatment of intracellular infections. The poor solubility and bitterness of enrofloxacin cause greater changes in its absorption in animals, which affects the clinical t...

AI Technical Summary

Problems solved by technology

Studies have reported that myristic acid, palmitic acid and stearic acid solid lipid nanoparticles prepared by hot-melt emulsification ultrasonography can improve the in vivo absorption and circulation time of enrofloxacin in mice, but the three fatty acid solid lipid nanocapsules The sealing rate is lower than 70%, and the drug loading is lower than 7.3%, which limits the possibility of its wide clinical application (Xie et al., 2011)

Images